Compile Data Set for Download or QSAR
Report error Found 42 Enz. Inhib. hit(s) with all data for entry = 13075
TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756431(US20250215011, Example 1)
Affinity DataIC50: 1.00E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756467(US20250215011, Example 33)
Affinity DataIC50: 1.00E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756466(US20250215011, Example 32)
Affinity DataIC50: 1.00E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756465(US20250215011, Example 31)
Affinity DataIC50: 1.00E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756461(US20250215011, Example 27)
Affinity DataIC50: 1.00E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756460(US20250215011, Example 26)
Affinity DataIC50: 1.00E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756439(US20250215011, Example 9)
Affinity DataIC50: 1.00E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756473(US20250215011, Example 39)
Affinity DataIC50: 1.00E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756470(US20250215011, Example 36)
Affinity DataIC50: 1.00E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756469(US20250215011, Example 35)
Affinity DataIC50: 1.00E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756468(US20250215011, Example 34)
Affinity DataIC50: 1.00E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756445(US20250215011, Example 15)
Affinity DataIC50: 1.00E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756444(US20250215011, Example 14)
Affinity DataIC50: 1.00E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756443(US20250215011, Example 13)
Affinity DataIC50: 1.00E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756441(US20250215011, Example 11)
Affinity DataIC50: 1.00E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756476(US20250215011, Example 43)
Affinity DataIC50: 1.00E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756440(US20250215011, Example 10)
Affinity DataIC50: 1.00E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756459(US20250215011, Example 25)
Affinity DataIC50: 1.00E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756457(US20250215011, Example 23)
Affinity DataIC50: 1.00E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756455(US20250215011, Example 21)
Affinity DataIC50: 1.00E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756454(US20250215011, Example 20)
Affinity DataIC50: 1.00E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756452(US20250215011, Example 18)
Affinity DataIC50: 1.00E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756464(US20250215011, Example 30)
Affinity DataIC50: 5.50E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756463(US20250215011, Example 29)
Affinity DataIC50: 5.50E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756462(US20250215011, Example 28)
Affinity DataIC50: 5.50E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756475(US20250215011, Example 41)
Affinity DataIC50: 5.50E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756474(US20250215011, Example 40)
Affinity DataIC50: 5.50E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756436(US20250215011, Example 6)
Affinity DataIC50: 5.50E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756472(US20250215011, Example 38)
Affinity DataIC50: 5.50E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756435(US20250215011, Example 5)
Affinity DataIC50: 5.50E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756471(US20250215011, Example 37)
Affinity DataIC50: 5.50E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756434(US20250215011, Example 4)
Affinity DataIC50: 5.50E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756433(US20250215011, Example 3)
Affinity DataIC50: 5.50E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756432(US20250215011, Example 2)
Affinity DataIC50: 5.50E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756447(US20250215011, Example 17)
Affinity DataIC50: 5.50E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756446(US20250215011, Example 16)
Affinity DataIC50: 5.50E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756442(US20250215011, Example 12)
Affinity DataIC50: 5.50E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756458(US20250215011, Example 24)
Affinity DataIC50: 5.50E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756456(US20250215011, Example 22)
Affinity DataIC50: 5.50E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756453(US20250215011, Example 19)
Affinity DataIC50: 5.50E+3nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756438(US20250215011, Example 8)
Affinity DataIC50: 1.00E+4nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM756437(US20250215011, Example 7)
Affinity DataIC50: 1.00E+4nMAssay Description:In some embodiments, the method of treating a depressive disorder, e.g., major depressive disorder, provides a therapeutic effect (e.g., as measured ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
10/26/2025
Entry Details
Go to US Patent